Clinical Trials (PDQ®) - National Cancer Institute

Page Options

Clinical Trial Questions?

Get Help:

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
No phase specified Treatment Completed 18 and over Other 1056757
Mistletoe, NCT00283478

Trial Description

Summary

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Further Study Information

RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.

Eligibility Criteria

Inclusion Criteria:

newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo

Karnofsky score 60% or greater

patients who will be treated with Gemcitabine

Trial Contact Information

Trial Lead Organizations/Sponsors

Kentuckiana Cancer Institute, PLLC

Renato Vincenzo LaRocca

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00283478
Information obtained from ClinicalTrials.gov on May 13, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.